2008-05-02: A few DRV Resistance Scores and Comments Updated
A few DRV scores and comments were updated. For more details follow this link
2008-04-29: Resistance Scores and Comments Updated
A few scores and comments were updated. For more details follow this link
2007-07-12: NNRTI Resistance Scores and Comments Updated: added drug TMC125
Scores and comments for TMC125, a new NNRTI drug, were added. For more details follow this link
2007-01-30: Three new programs launched: ART-AiDE, eCARE, and CPR
Antiretroviral Therapy - Acquisition and Display Engine (ART-AiDE) makes it
possible to generate a permanent electronic and graphical record of a
patient's antiretroviral treatment (ARV) history, plasma HIV-1 RNA levels,
CD4 counts, and genotypic resistance data. The electronic Clinical
Antiretroviral Resistance Estimator (eCARE) matches submitted ARVs with
sequences in the Stanford HIV Drug Resistance Database obtained from
persons with matching ARV histories. eCARE, which is an early stage of
development, is available through ART-AiDE. The link to ART-AiDE is provided on the right in the home page.
Calibrated Population Resistance (CPR) analysis tool determines the
prevalence of NRTI, NNRTI, and PI resistance in a set of protease and/or RT
sequences using a standardized analysis that enables users to compare their
results to those of other published studies. Although designed primarily
for studies of primary HIV drug resistance, CPR can be applied to any HIV
protease and/or RT sequence set. The link to CPR is provided under the section "ANALYSIS TOOLS" in the home page.
2006-12-04: Few PI Resistance Scores Updated
A few scores for PI drugs were updated. For more details follow this link
2006-11-21: Resistance Scores and Comments Updated
A few scores for PI drugs and comments were updated, especially TPV. fAPV was renamed FPV and TMC114 was renamed DRV. For more details follow this link
2006-10-11: PI Resistance Scores Updated
A few scores for PI drugs were updated, especially TMC 114. For more details follow this link
2006-09-18: ANRS Resistance Algorithm Updated
Scores for ANRS resistance algorithm were updated to 2006 July version. For more details follow this link to their site
2006-09-18: PI Resistance Scores Updated
Scores and comments for PI drugs were updated, especially TMC 114. For more details follow this link
2006-08-22: PI Resistance Summaries Updated
PI resistance summary pages have been updated to reflect recently reported data relevant to atazanavir (ATV), tipranavir (TPV), and darunavir (DRV, TMC114). Most of the changes reflect data from salvage therapy trials. Sequences from TPV and DRV treated persons have not yet been submitted to the database. TPV and DRV drug susceptibility data have also not yet been submitted to the database. Researchers who would like to submit such data should contact us at HIVDB.
2006-05-30: Positions available
We are seeking two post-doctoral fellows to perform studies of HIV sequence variation, molecular evolution, population genetics, and antiviral drug resistance; to develop software to assist other researchers performing similar analyses; and to further the development of the Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu).
Candidates should have degrees in biology, biomedical informatics, or statistics and be motivated to innovate and publish. Candidates will have to become highly knowledgeable about the biological and clinical aspects of HIV drug resistance and how the data representing this knowledge is organized in the Stanford database. Candidates will need to be able to write their own programs for querying the Stanford database and for performing statistical and machine learning analyses of data within the Stanford database as well as of data from additional ongoing collaborations. Ideally, one candidate will have a stronger computer programming background and will contribute to improving the database and its tools and another will have a stronger analytic background with statistical skills and an understanding of molecular evolution and population genetics analyses.
Please e-mail your CV, a brief statement, and the names, telephone numbers, and e-mail addresses of three references to HIVDB.
2005-05-25: Letter Written to the FDA
Show us the data! To better meet their responsibility, the FDA should encourage pharmaceutical companies to release the data supporting the activity of new HIV drugs against drug-resistant viruses. The full text of the letter »
